Table 4.
Univariate and multivariate cox regression analysis for disease-free survival and overall survival
| Variables |
DFS
|
OS
|
||||||
|
HR (95%CI)1
|
P value1
|
HR (95%CI)2
|
P value2
|
HR (95%CI)1
|
P value1
|
HR (95%CI)2
|
P value2
|
|
| Age (≥ 60/< 60), years | 1.092 (0.771-1.451) | 0.551 | 1.083 (0.689-1.337) | 0.384 | ||||
| Gender (male/female) | 1.208 (0.669-1.391 | 0.804 | 1.221 (0.773-1.502) | 0.448 | ||||
| BMI > 24 kg/m2 (present/absent) | 1.122 (0.983-1.304) | 0.37 | 1.141 (0.725-1.408) | 0.283 | ||||
| History of DM (present/absent) | 1.178 (0.694-1.303) | 0.327 | 0.933 (0.791-1.273) | 0.739 | ||||
| History of smoke (present/absent) | 1.228 (0.993-1.401) | 0.225 | 1.204 (1.033-1.471) | 0.131 | ||||
| History of drinking (present/absent) | 1.198 (0.989-1.377) | 0.336 | 1.331 (1.085-1.503) | 0.106 | ||||
| Hypertension (present/absent) | 0.942 (0.793-1.228) | 0.601 | 1.076 (0.880-1.202) | 0.441 | ||||
| Cardiovascular disease (present/absent) | 1.213 (1.004-1.381) | 0.201 | 1.118 (0.969-1.307) | 0.116 | ||||
| CEA (≥ 5/< 5), μg/mL | 1.896 (2.231-3.884) | < 0.001 | 2.031 (1.990-3.551) | 0.014 | 1.974 (1.771-3.025) | < 0.001 | 1.894 (1.575-2.928) | 0.006 |
| CA19-9 (≥ 37/< 37), ng/mL | 1.552 (1.383-2.452) | 0.017 | 1.714 (1.508-2.839) | 0.021 | 1.692 (1.493-2.921) | 0.032 | 1.554 (1.399-2.680) | 0.041 |
| T stage (4/3) | 1.708 (1.620-2.337) | 0.015 | 1.599 (1.483-2.091) | 0.044 | 1.801 (1.674-2.395) | 0.009 | 1.869 (1.503-2.061) | 0.029 |
| N stage (2/1) | 2.088 (1.854-2.827) | < 0.001 | 1.880 (1.769-2.557) | 0.007 | 1.822 (1.701-2.223) | 0.015 | 1.777 (1.582-2.330) | 0.033 |
| Tumor location (RCC/LCC) | 1.695 (1.503-2.241) | 0.025 | 1.597 (1.415-1.998) | 0.038 | 1.839 (1.696-2.377) | 0.018 | 1.683 (1.503-2.117) | 0.040 |
| Tumor size (≥ 4.5/< 4.5), cm | 2.035 (1.897-2.730) | 0.006 | 1.885 (1.747-2.381) | 0.023 | 1.920 (1.593-2.409) | 0.009 | 1.803 (1.544-2.019) | 0.024 |
| Tumor differentiation (PD/MD) | 2.913 (1.954-3.409) | < 0.001 | 2.447 (2.019-2.927) | 0.013 | 1.899 (1.704-2.988) | < 0.001 | 1.901 (1.695-2.723) | 0.018 |
| Vascular invasion (present/absent) | 2.189 (1.655-3.231) | < 0.001 | 2.033 (1.779-2.968) | 0.008 | 1.909 (1.664-2.817) | 0.023 | 1.872 (1.553-2.482) | 0.041 |
| Perineural invasion (present/absent) | 1.689 (1.347-2.086) | 0.030 | 1.607 (1.306-1.997) | 0.039 | 1.822 (1.606-2.571) | 0.008 | 1.749 (1.500-2.288) | 0.036 |
| FPG (≥ 7/< 7), mmol/L | 2.829 (2.235-4.026) | < 0.001 | 2.684 (2.107-3.941) | < 0.001 | 2.316 (1.994-3.561) | 0.002 | 2.105 (1.890-2.961) | 0.019 |
| HbA1c (≥ 7/< 7), % | 2.667 (2.403-3.559) | < 0.001 | 2.344 (2.101-3.285) | 0.006 | 2.258 (2.009-2.891) | 0.0012 | 2.119 (1.943-3.007) | 0.021 |
Univariate analysis.
Multivariate analysis.
DFS: Disease-free survival; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; BMI: Body mass index; DM: Diabetes mellitus; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 199; LCC: Left-side colon cancer; RCC: Right-side colon cancer; MD: Moderately differentiated; PD: Poorly differentiated; FPG: Fasting plasma glucose; HbA1c: Glycosylated hemoglobin.